An association between a novel hyper inflammatory condition in children and SARS-CoV-2 was recently termed as multisystem inflammatory syndrome (in children) (MIS-C). MIS-C is a dangerous pediatric complication of COVID-19. MIS-C was originally identified as a unique life-threatening hyperinflammatory illness in April 2020. SARS-CoV-2 infection generally causes MIS-C to manifest 4-6 weeks later, suggesting that the virus may serve as a trigger in people with specific genetic predispositions. MIS-C is an inflammatory syndrome which can affect any organ system. The most common symptoms are fever and GI symptoms. Patients with MIS- C may also appear with an irregular ECG and an increase in inflammatory markers. Resuscitation is the first line of treatment, and point-of-care ultrasound is used to carefully identify whether the shock is cardiac or vasodilatory. In most cases, patients need to be admitted to an ICU. Treatment should include IV immunoglobulin, anticoagulation, and consideration of corticosteroids. For refractory cases Interleukin-1 and/or interleukin-6 inhibitors may be considered. Thus, Growing awareness of MIS-C, a disease linked to morbidity and death, as a potential consequence in young COVID-19 patients. It's crucial for emergency medical professionals to understand how to identify and manage this disease.